^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Folate receptor 1 inhibitor

    Related drugs:
    Apply
    A Study of CBP-1018 in Patients With Advanced Solid Tumors (NCT04928612)
    Phase 1
    Coherent Biopharma (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    08/28/2024
    Initiation :
    11/04/2021
    Primary completion :
    10/01/2024
    Completion :
    12/01/2024
    FOLR1
    |
    CBP-1018
    ITIL-306 in Advanced Solid Tumors (NCT05397093)
    Phase 1
    Instil Bio
    Active, not recruiting
    Last update posted :
    03/05/2024
    Initiation :
    08/24/2022
    Primary completion :
    07/01/2025
    Completion :
    11/01/2039
    EGFR • KRAS • ALK • BRCA
    |
    BRCA mutation
    |
    cyclophosphamide • ITIL-306
    Phase I Study of MOv18 IgE (CRUKD14/001) (NCT02546921)
    Phase 1
    Cancer Research UK
    Completed
    Last update posted :
    06/05/2023
    Initiation :
    02/16/2016
    Primary completion :
    06/22/2021
    Completion :
    07/30/2021
    MUC16
    |
    MUC16 elevation
    |
    MOv18 IgE
    Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer (NCT02593227)
    Phase 2
    Marker Therapeutics, Inc.
    Completed
    Last update posted :
    07/19/2021
    Initiation :
    04/01/2016
    Primary completion :
    07/15/2021
    Completion :
    07/15/2021
    HER-2 • FOLR1
    |
    FOLR1 expression
    |
    cyclophosphamide • TPIV200 • cyclophosphamide intravenous
    A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung (MORAb-003-009) (NCT01218516)
    Phase 2
    Morphotek
    Completed
    Last update posted :
    08/20/2020
    Initiation :
    06/27/2011
    Primary completion :
    12/15/2012
    Completion :
    11/01/2013
    FOLR1
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • farletuzumab (MORAB-003)
    A Study of MORAb-003 in Patients With Solid Tumor (MORAB-003-J081-102) (NCT01049061)
    Phase 1
    Eisai Co., Ltd.
    Completed
    Last update posted :
    06/11/2020
    Initiation :
    01/01/2010
    Primary completion :
    01/01/2013
    Completion :
    02/01/2013
    FOLR1
    |
    FOLR1 expression
    |
    farletuzumab (MORAB-003)
    Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors (NCT01999738)
    Phase 1
    Endocyte
    Completed
    Last update posted :
    02/07/2019
    Initiation :
    10/01/2013
    Primary completion :
    12/31/2017
    Completion :
    04/26/2018
    EGFR • PD-L1 • ALK • BRCA1 • BRCA2 • ROS1 • BRCA
    |
    BRCA mutation
    |
    folate-tubulysin (EC1456)
    Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy (MORAb-003-002) (NCT00318370)
    Phase 2
    Morphotek
    Completed
    Last update posted :
    09/09/2015
    Initiation :
    05/01/2006
    Primary completion :
    02/01/2010
    Completion :
    06/01/2010
    MUC16
    |
    carboplatin • paclitaxel • docetaxel • farletuzumab (MORAB-003)